Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
1.660
+0.010 (0.61%)
Sep 4, 2026, 12:08 PM EDT - Market open
Alaunos Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.12 | 1.39 | 1.09 | 6.06 | 39.06 | 76.05 |
Cash & Short-Term Investments | 0.12 | 1.39 | 1.09 | 6.06 | 39.06 | 76.05 |
Cash Growth | -95.69% | 26.95% | -82.00% | -84.48% | -48.64% | -33.91% |
Accounts Receivable | - | 0 | 0.01 | 0 | 0 | 1.11 |
Receivables | - | 0 | 0.01 | 0 | 0 | 1.11 |
Prepaid Expenses | 0.32 | 0.38 | 1.66 | 2.2 | 0.8 | 1.67 |
Restricted Cash | - | - | - | - | 13.94 | - |
Other Current Assets | 0.22 | 0.22 | - | - | - | - |
Total Current Assets | 0.67 | 1.99 | 2.76 | 8.26 | 53.8 | 78.83 |
Property, Plant & Equipment | 0.07 | 0.09 | - | 0 | 10.6 | 15.36 |
Long-Term Deferred Charges | 0.78 | 0.89 | - | - | - | - |
Other Long-Term Assets | - | - | - | - | 0.54 | 0.67 |
Total Assets | 1.52 | 2.97 | 2.76 | 8.26 | 64.94 | 94.87 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.73 | 0.61 | 0.52 | 0.62 | 1.39 | 1.37 |
Accrued Expenses | 0.13 | 0.2 | 0.18 | 1.34 | 5.45 | 6.08 |
Current Portion of Long-Term Debt | - | - | - | - | 16.77 | 7.87 |
Current Portion of Leases | - | - | - | - | 0.56 | 0.73 |
Total Current Liabilities | 0.86 | 0.81 | 0.69 | 1.96 | 24.17 | 16.04 |
Long-Term Debt | - | - | - | - | - | 16.25 |
Long-Term Leases | - | - | - | - | 2.19 | 4.52 |
Other Long-Term Liabilities | - | - | - | - | 0.03 | -0 |
Total Liabilities | 0.86 | 0.81 | 0.69 | 1.96 | 26.38 | 36.81 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0.02 | 0.22 |
Additional Paid-In Capital | 927.23 | 926.77 | 922.51 | 922.07 | 919.17 | 900.69 |
Retained Earnings | -926.58 | -924.62 | -920.45 | -915.77 | -880.63 | -842.85 |
Total Common Equity | 0.65 | 2.15 | 2.06 | 6.31 | 38.56 | 58.06 |
Shareholders' Equity | 0.65 | 2.15 | 2.06 | 6.31 | 38.56 | 58.06 |
Total Liabilities & Equity | 1.52 | 2.97 | 2.76 | 8.26 | 64.94 | 94.87 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | - | 19.51 | 29.37 |
Net Cash (Debt) | 0.12 | 1.39 | 1.09 | 6.06 | 19.55 | 46.69 |
Net Cash Growth | -95.69% | 26.95% | -82.00% | -68.99% | -58.13% | -57.65% |
Net Cash Per Share | 0.05 | 0.71 | 0.68 | 3.79 | 13.50 | 32.66 |
Filing Date Shares Outstanding | 2.54 | 2.38 | 1.6 | 1.6 | 1.6 | 1.43 |
Total Common Shares Outstanding | 2.49 | 2.35 | 1.6 | 1.6 | 1.6 | 1.43 |
Working Capital | -0.2 | 1.18 | 2.06 | 6.31 | 29.63 | 62.79 |
Book Value Per Share | 0.26 | 0.92 | 1.29 | 3.94 | 24.15 | 40.52 |
Tangible Book Value | 0.65 | 2.15 | 2.06 | 6.31 | 38.56 | 58.06 |
Tangible Book Value Per Share | 0.26 | 0.92 | 1.29 | 3.94 | 24.15 | 40.52 |
Machinery | - | 0.1 | 0.02 | 0.02 | 7.42 | 7.64 |
Leasehold Improvements | - | - | - | - | 9.56 | 9.47 |